

Review



Meets Learning Need Codes 2000, 2100, and 2040. To take the Continuing Professional Education quiz for this article, log in to ADA's Online Business Center at www.eatright.org/obc, click the "Journal Article Quiz" button, click "Additional Journal CPE Articles," and select this article's title from a list of available quizzes.

Fructose: Metabolic, Hedonic, and Societal Parallels with Ethanol

ROBERT H. LUSTIG, MD

ABSTRACT

Rates of fructose consumption continue to rise nationwide and have been linked to rising rates of obesity, type 2 diabetes, and metabolic syndrome. Because obesity has been equated with addiction, and because of their evolutionary commonalities, we chose to examine the metabolic, hedonic, and societal similarities between fructose and its fermentation byproduct ethanol. Elucidation of fructose metabolism in liver and fructose action in brain demonstrate three parallelisms with ethanol. First, hepatic fructose metabolism is similar to ethanol, as they both serve as substrates for de novo lipogenesis, and in the process both promote hepatic insulin resistance, dyslipidemia, and hepatic steatosis. Second, fructosylation of proteins with resultant superoxide formation can result in hepatic inflammation similar to acetaldehyde, an intermediary metabolite of ethanol. Lastly, by stimulating the "hedonic pathway" of the brain both directly and indirectly, fructose creates habituation, and possibly dependence; also paralleling ethanol. Thus, fructose induces alterations in both hepatic metabolism and central nervous system energy signaling, leading to a "vicious cycle" of excessive consumption and disease consistent with metabolic syndrome. On a societal level, the treatment of fructose as a commodity exhibits market similarities to ethanol. Analogous to ethanol, societal efforts to reduce fructose consumption will likely be necessary to combat the obesity epidemic.

J Am Diet Assoc. 2010;110:1307-1321.

R. H. Lustig is professor of pediatrics, Division of Endocrinology, University of California, San Francisco.

Address correspondence to: Robert H. Lustig, MD, Division of Pediatric Endocrinology, Box 0434, Room S-679, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143-0434. E-mail: rlustig@peds.ucsf.edu

Manuscript accepted: March 15, 2010.

Copyright © 2010 by the American Dietetic Association.

0002-8223/1307-0000

doi: 10.1016/j.jada.2010.06.008

The last 30 years has witnessed an inexorable rise in obesity, diabetes, and metabolic syndrome coincident with a rise in daily calorie intake (1). Aside from quantitative overconsumption, various macronutrients have been postulated to contribute to the metabolic syndrome (2,3). Some suggest that specific dietary fats, such as saturated and *trans* fats, are the culprit (4-6), while others suggest that a deficiency of monounsaturated lipids, such as olive oil (oleic acid) (7) or linoleic acid (8), are implicated. However, our absolute consumption of dietary fat has not changed in these last 30 years (9), and high-fat, low-carbohydrate diets appear to be protective against the metabolic syndrome (10). Although epidemiologic studies associate light to moderate ethanol consumption with improved insulin sensitivity (11) and wine consumption with reduced cardiovascular risk (12), other cross-sectional (13,14) and prospective (15) studies implicate a dose-dependent effect of larger doses of ethanol in the pathogenesis of insulin resistance and the metabolic syndrome, especially in beer and shochu, which provide a large dose of carbohydrate in addition to ethanol (13,14).

Another likely culprit, and the focus of this review, is the monosaccharide fructose. An ever-increasing percentage of calories in the American diet are derived from fructose. Before 1900, Americans consumed approximately 15 g/day fructose (4% of total calories), mainly through fruits and vegetables. Before World War II, fructose intake had increased to 24 g/day; by 1977, 37 g/day (7% of total calories); by 1994, 55 g/day (10% of total calories); and current estimates put fructose consumption by adolescents at 73 g/day (12% of total calories) (16). Current fructose consumption has incrementally increased fivefold in the last century and doubled in the last 30 years. Disappearance data from the Economic Research Service of the US Department of Agriculture support this secular trend. These data document partial substitution for sucrose by high-fructose corn syrup; however, annual per capita total caloric sweetener usage increased from 73 to 95 lb in that interval (17). Although high-fructose corn syrup in soda has received most of the attention (18,19), high fruit juice intake (sucrose) is also associated with childhood obesity (20), although it is not captured in the Economic Research Service. Thus, after adjustment for juice intake, per capita consumption of fructose or fructose-containing disaccharides is at ap-

proximately 156 lb/year or 0.4 lb/day for the average American.

Although originally proposed as the ideal sweetener for people with diabetes because of its inability to raise serum glucose levels and its insulin-independent metabolism, many (21-28), although certainly not all (29), investigators have elaborated fructose's unique hepatic properties and have indirectly implicated fructose in the dual epidemics of obesity and type 2 diabetes and its primacy in the pathogenesis of the metabolic syndrome. The American Heart Association has recently called for a reduction in added sugars intake to help quell these epidemics (30).

The purpose of this work is to highlight, in both animal and human studies, the unique aspects of hepatic fructose metabolism, central nervous system fructose action, and their associations with obesity and the metabolic syndrome, and to draw parallels to the mechanisms of action of ethanol. Using PubMed and the substrate key terms *fructose* or *ethanol*, combined with the effector terms *de novo lipogenesis*, *hypertriglyceridemia*, *steatosis* or *fatty liver*, *insulin resistance*, *metabolic syndrome*, *reactive oxygen species*, and *addiction*, a review of the literature on the secular trends of fructose consumption, hepatic glucose, ethanol, and fructose metabolism, carbohydrate-protein adduct and reactive oxygen species formation, and of sugar as an addictive substance, between the years 1966 and 2009, was conducted. Mechanistic studies in animals that addressed directionality of effect, along with correlative or mechanistic data in humans that supported or detracted from such mechanisms were included. After syntheses of these data, consultations with experts in the field of fructose metabolism, hepatic lipid metabolism, and addiction were obtained to establish veracity of these findings (listed in Acknowledgments).

HEPATIC INSULIN RESISTANCE AND THE METABOLIC SYNDROME

The pathogenesis of the metabolic syndrome remains a conundrum; to the point where some have called into question its very existence (31). One reason for this puzzle is the phenomenon of "selective hepatic insulin resistance" seen in the metabolic syndrome (32). Insulin normally exerts its effects on liver metabolism through two primary metabolic pathways. In the first, phosphorylation of the forkhead protein Foxo1 occurs, excluding it from the nucleus of the hepatocyte, and thus reducing transcription of genes for enzymes involved in gluconeogenesis, thus maintaining euglycemia (33,34). The second pathway is the activation of sterol regulatory element binding protein-1c (SREBP-1c). This transcription factor activates *de novo* lipogenesis to turn excess energy from either fat or carbohydrate into triglyceride, which is then packaged into very low density lipoproteins (VLDL) for hepatic export and peripheral storage in adipocytes.

Complete hepatic insulin resistance, such as seen in the liver insulin receptor knockout mouse (35), results in both lack of Foxo1 phosphorylation (with resultant gluconeogenesis and hyperglycemia) and lack of SREBP-1c activation (with lack of triglyceride synthesis). In contrast, hepatic insulin resistance in metabolic syndrome is "selective." Foxo1 remains dephosphorylated (promoting

gluconeogenesis, hepatic glucose output, and driving reflex hyperinsulinemia), but SREBP-1c is activated (promoting triglyceride synthesis, dyslipidemia, and other negative downstream effects, see "Hepatic Fructose Metabolism"). The reason for this uncoupling of insulin's two main hepatic signaling pathways remains unclear.

DIFFERENTIAL HEPATIC METABOLISM OF ENERGY SUBSTRATE

To explain the dichotomy of selective insulin resistance in the pathogenesis of metabolic syndrome, it is essential to delineate the hepatic metabolism of three energy substrates: glucose, ethanol, and fructose. As an illustration, in each case, we will follow a 120-kcal oral bolus of each substrate. However, it should be noted that the hepatic metabolism of each substrate delineated below is subject to numerous environmental and behavioral factors, such as ambient temperature, altitude, sleep debt, smoking, thyroid status, and, most importantly, physical activity. The following breakdown is meant to depict a sedentary American adult.

Hepatic Glucose Metabolism

Glucose is the preferred substrate for energy metabolism. Each cell in the body possesses a glucose transporter (Glut1 through Glut4 constitute the majority) to facilitate transport of glucose into the cell for energy utilization. Upon ingestion of 120 kcal of glucose (eg, two slices of white bread) (Figure 1), plasma glucose levels rise and insulin is released by the pancreas through glucose stimulation of β -cell depolarization via the Glut2 transporter. Ninety-six kilocalories (80%) of the glucose bolus are utilized by other organs immediately (36). Only 24 kcal (20%) enter the liver through the Glut2 transporter.

Insulin binds to the hepatic insulin receptor, activating its endogenous B-chain tyrosine kinase, which promotes the tyrosine phosphorylation of insulin receptor substrate-1, which increases the activity of phosphatidylinositol-3 kinase, inducing the transcription factor Akt. Akt activates three distinct pathways of hepatic insulin action. The first is the phosphorylation of the forkhead protein Foxo1, downregulating gluconeogenesis to maintain euglycemia (34). The second is the increase of SREBP-1c, which then activates the enzyme glucokinase, fixing glucose in the hepatocyte by forming glucose-6-phosphate. The third is activation of glycogen synthase kinase, which then activates glycogen synthase. The majority of glucose-6-phosphate (approximately 20 kcal, depending on the amplitude of the insulin signal) is deposited in the liver as glycogen, the storage carbohydrate. The liver can store large amounts of glycogen without experiencing dysfunction or damage, as demonstrated by the continued normal hepatic function into adulthood of patients with glycogen storage diseases (37).

Only a small amount of glucose-6-phosphate (the exact amount is dependent on quantity of other substrates, and magnitude of insulin action) is broken down by the Embden-Meyerhoff glycolytic pathway to pyruvate. Pyruvate enters the mitochondria, where it is converted to acetyl-CoA, which then participates in the Krebs tricarboxylic acid (TCA) cycle to generate adenosine triphosphate, the chemical storage form of energy, carbon dioxide, and wa-

Metabolism of Glucose




Figure 1. Hepatic glucose metabolism. Of an ingested glucose load, 20% is metabolized by the liver. Under the action of insulin, glycogen synthase is increased, and the majority of the glucose load is stored as glycogen. While insulin activation of sterol response element binding protein-1c (SREBP-1c) activates the lipogenic pathway, there is little citrate formed to act as substrate for lipogenesis. In addition, insulin action on the liver phosphorylates forkhead protein-1 (Foxo1), excluding it from the nucleus, and suppressing the enzymes involved in gluconeogenesis (gluconeogenesis). ADP=adenosine diphosphate. ATP=adenosine triphosphate. GNG=gluconeogenesis. IRS-1=insulin receptor substrate-1. TG=triglyceride.

ter. The hepatic TCA cycle has a relatively fixed maximum velocity, modulated only by thyroid status, cold exposure, altitude, and exercise (38,39). Thus, whatever tiny fraction of pyruvate is not metabolized by the mitochondria exits back into the cytoplasm as citrate through the “citrate shuttle” (40). This small amount of cytoplasmic citrate can serve as substrate for the process of de novo lipogenesis (DNL). In DNL, the enzyme adenosine triphosphate citrate lyase cleaves citrate to acetyl-CoA, the enzyme acetyl-CoA carboxylase carboxylates acetyl-CoA to form malonyl-CoA, and the enzyme fatty acid synthase adds serial acetyl-CoAs to the carbon backbone. These enzymes are activated serially under the transcriptional regulation of SREBP-1c to metabolize citrate into fatty acyl-CoA (41), which is then esterified with glycerol

to form triglyceride. From there, triglyceride binds to apolipoprotein B (apoB) to form VLDL (measured peripherally in the triglyceride fraction), which are transported out of the liver for storage in adipocytes, and can serve as substrate for peripheral energy metabolism, but in excess will promote atherogenesis and/or obesity. Thus, only a tiny fraction of glucose can be hepatically metabolized to VLDL, which could contribute slowly to cardiovascular disease during a lifetime.

Hepatic Ethanol Metabolism

Ethanol is a naturally occurring energy substrate and, in small doses, may confer health benefits, but it is also recognized in acute large quantities as a central nervous

Metabolism of Ethanol




Figure 2. Hepatic ethanol metabolism. Of an ingested load, 80% reaches the liver. Ethanol induces: de novo lipogenesis and dyslipidemia; c-jun N-terminal kinase (JNK-1) activation, which serine phosphorylates hepatic insulin receptor substrate-1 (IRS-1), rendering it inactive, and contributing to hepatic insulin resistance, which promotes hyperinsulinemia and influences substrate deposition into fat; hepatic lipid droplet formation, leading to steatosis; and stimulation of the reward pathway, promoting continuous consumption. ACC=acetyl CoA carboxylase. ACL=adenosine triphosphate citrate lyase. CPT-1=carnitine palmitoyl transferase-1. FAS=fatty acid synthase. FFA=free fatty acids. IR=insulin resistance. IRS-1=insulin receptor substrate-1. JNK-1=c-jun N-terminal kinase 1. LPL=lipoprotein lipase. MTP=microsomal transfer protein. PKC ϵ =protein kinase C- ϵ . SREBP-1c=sterol regulatory element binding protein-1c. TCA=tricarboxylic acid. TG=triglyceride.

system toxin and in chronically large quantities as a hepatotoxin. Although epidemiologic studies associate light to moderate ethanol consumption with improved insulin sensitivity (11) and wine consumption with reduced cardiovascular risk (12), other cross-sectional (13,14) and prospective (15) studies implicate a dose-dependent effect of the chronic consumption of larger doses of ethanol, especially in beer, shochu, and spirits (13,14), in the genesis of insulin resistance and metabolic syndrome.

The hepatic metabolism of ethanol is quite dichotomous from that of glucose (Figure 2). Upon oral ingestion of 120 kcal of ethanol (eg, 1.5 oz hard spirits at 80 proof, or 40%),

approximately 10% is metabolized by the stomach and stomach and intestine in a “first-pass” effect before entry into the portal circulation (42). Another 10% are metabolized by muscle and kidney. So approximately 96 calories reach the liver, accounting for four times the substrate as for glucose. Ethanol enters the hepatocyte through osmosis and does not stimulate insulin secretion. Once inside the liver, ethanol bypasses glycolysis and is converted by alcohol dehydrogenase 1B to form acetaldehyde, which, because of its free aldehyde, can generate reactive oxygen species (ROS) formation and toxic damage (43) if not quenched by hepatic antioxidants such as glutathione or ascorbic acid (see “ROS Formation”) (44).

Figure 3. Hepatic fructose metabolism. Of an ingested sucrose load, 20% of the glucose and 100% of the fructose is metabolized by the liver. Fructose induces substrate-dependent phosphate depletion, which increases uric acid and contributes to hypertension through inhibition of endothelial nitric oxide synthase and reduction of nitric oxide (NO); de novo lipogenesis (DNL) and dyslipidemia; hepatic lipid droplet formation and steatosis; muscle insulin resistance; c-jun N-terminal kinase (JNK-1) activation, contributing to hepatic insulin resistance, which promotes hyperinsulinemia and influences substrate deposition into fat; increased forkhead protein-1 (Foxo1), promoting gluconeogenesis and hyperglycemia; and central nervous system (CNS) hyperinsulinemia, which antagonizes central leptin signaling and promotes continued energy intake. ACC=acetyl CoA carboxylase. ACL=adenosine triphosphate citrate lyase. ACSS2=acyl-CoA synthetase short-chain family member 2. AMP=adenosine monophosphate. ApoB=apolipoprotein B. ChREBP=carbohydrate response element binding protein. CPT-1=carnitine palmitoyl transferase-1. FAS=fatty acid synthase. FFA=free fatty acids. Glut 5=glucose transporter 5. Glut2=glucose transporter 2. Glut4=glucose transporter 4. GNG=gluconeogenesis. GSK=glycogen synthase kinase. IR=insulin resistance. IRS-1=insulin receptor substrate-1. LPL=lipoprotein lipase. MKK7=mitogen activated protein kinase kinase 7. MTP=microsomal transfer protein. PFK=phosphofructokinase. PGC-1 β =peroxisome proliferator-activated receptor- γ coactivator-1 β . PI3K=phosphatidyl inositol-3-kinase. PKC ϵ =protein kinase C- ϵ . PP2A=protein phosphatase 2a. SREBP-1c=sterol regulatory element binding protein-1c. VLDL=very-low-density lipoprotein.

Acetaldehyde is then quickly metabolized by the enzyme aldehyde dehydrogenase 2 to the intermediary acetic acid. From there, acetic acid is metabolized by the enzyme acyl-CoA synthetase short-chain family member 2 to form acetyl-CoA, which can then enter the mitochondrial TCA cycle (as per glucose, see “Hepatic Glucose Metabolism”); or, in the presence of other caloric substrate, it is more likely to participate in synthesis of fatty

acids through DNL (as per fructose, see “Hepatic Fructose Metabolism”). Furthermore, acetaldehyde stimulates SREBP-1c, activating the enzymes of DNL (45). Although the absolute rate of DNL of ethanol (ie, that which is metabolized to VLDL) is relatively small, fractional DNL increases from 1% at baseline to 31% after an ethanol bolus (46); thus, the liver is primed to convert ethanol to lipid.

In the process of DNL, the intermediary malonyl-CoA is formed in excess. However, malonyl-CoA is a steric inhibitor of the mitochondrial enzyme carnitine palmitoyl transferase-1 (47). Carnitine palmitoyl transferase-1 is the key rate-limiting and regulatory step in mitochondrial β -oxidation; the fatty acid transporter carnitine must be regenerated for transesterification and import of fatty acids into the mitochondrial matrix to generate two-carbon fragments for ketone formation (48). Furthermore, ethanol blocks fatty acid β -oxidation through inhibition of both peroxisome proliferation-activated receptor- α and adenosine monophosphate-activated protein kinase, which leads to decreased phosphorylation and resultant increased activity of acetyl-CoA carboxylase, increased levels of malonyl-CoA, and decreased activity of carnitine palmitoyl transferase-1 (49). Thus, increased DNL inhibits intrahepatic lipid β -oxidation, resulting in further intrahepatic lipid buildup (45,50).

The principal exit strategy for intrahepatic lipid is the export of VLDL; its synthesis depends on microsomal triglyceride transfer protein (MTP) for correct apoB100 protein folding prior to export. Reduction of hepatic peroxisome proliferation-activated receptor- α by ethanol downregulates MTP activity (51). Hepatic triglyceride availability is the major determinant of the VLDL secretion rate, but MTP activity seems to determine VLDL size and subsequent rates of clearance in the plasma (52). Similarly, ethanol suppression of MTP alters VLDL production and lipid export machinery (48) to increase VLDL production and contribute to hypertriglyceridemia (53-55).

Lastly, ethanol is a known contributor to hepatic insulin resistance (56,57). Although the mechanism is still unclear, dyslipidemia and hepatic insulin resistance may be due to hepatic diacylglycerol (DAG) and triglyceride accumulation seen in hepatic steatosis, with resultant activation of the enzyme c-jun N-terminal kinase 1 (JNK-1; see "Hepatic Fructose Metabolism") (58).

Hepatic Fructose Metabolism

Although the intestine and kidney possess the Glut5 transporter to resorb fructose into the bloodstream, only the liver possesses the Glut5 fructose transporter in order to metabolize fructose. Upon ingestion of 120 kcal of sucrose (eg, 8 oz of orange juice; composed of 60 kcal fructose and 60 kcal glucose) (Figure 3), the overwhelming majority of the 60-kcal fructose bolus reaches the liver, along with 20% of the glucose bolus (12 kcal), for a total of 72 kcal; thus, the liver must handle triple the substrate as it did for glucose alone (36).

Phosphate Depletion and Hypertension

In the liver, fructose is converted to fructose-1-phosphate by the enzyme fructokinase. This is an adenosine triphosphate-requiring reaction (59), depleting available intracellular phosphate. Phosphorylation of this large substrate load leads to activation of the scavenger enzyme adenosine monophosphate deaminase-1, which recoups intracellular phosphate by converting the adenosine phosphate breakdown products (adenosine diphosphate, adenosine monophosphate, and inosine monophosphate) to the cellular waste product uric acid (60).

Buildup of urate in the circulation inhibits endothelial nitric oxide synthase, resulting in decreased nitric oxide in the vasculature. Nitric oxide is an endogenous vascular smooth muscle relaxant; its depletion by urate results in hypertension (61,62).

Rodent models demonstrate that a high-fructose diet leads to hypertension and renovascular damage (63). Recently, sugar consumption has been correlated with uric acid concentrations in American adults (64). Similarly, soft drink consumption in adolescents in the recent National Health and Nutrition Examination Survey evaluation demonstrates a positive relationship with uric acid levels and with systolic hypertension (65). Lastly, soft drink consumption correlates with blood pressure elevation in adolescents, although concurrent caffeine ingestion may be a complicating variable (66). Furthermore, inhibition of uric acid synthesis by allopurinol reduces blood pressure in obese adolescents (67).

DNL

In contrast to glucose's conversion to glycogen, the fructose-1-phosphate load enters the Embden-Meyerhoff glycolytic cascade. The majority of fructose-1-phosphate is metabolized directly to pyruvate, with the resultant large volume of acetyl-CoA entering the mitochondrial TCA cycle. The liver mitochondria cannot metabolize the entire fructose-derived pyruvate/acetyl-CoA substrate excess; any extra will exit the mitochondria into the cytoplasm as citrate via the "citrate shuttle" (40). Alternatively, a proportion of early glycolytic intermediaries will recombine to form fructose-1,6-bisphosphate, which then also combines with glyceraldehyde to form xylulose-5-phosphate (68). Xylulose-5-phosphate is a potent stimulator of protein phosphatase 2A (69), which activates carbohydrate response element binding protein (70), stimulating the activity of all three DNL enzymes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase, which then rebuild the excess cytoplasmic citrate into fatty acyl-CoA and free fatty acids (FFA). Furthermore, fructose also stimulates peroxisomal proliferator-activated receptor- γ coactivator-1 β , a transcriptional coactivator for SREBP-1c, which further accentuates DNL enzymatic activity (71).

Excess accumulation of metabolites of DNL is seen in both human and rat models of steatosis (72,73). For instance, tracer studies in obese subjects with steatosis show that 26.1% of the intrahepatic lipid pool occurs through the process of DNL (74). On a typical high-fat diet, lean subjects exhibited <3% (1 to 2 g/day) of carbohydrate (CHO) converted to FFA by DNL (75,76). However, obese insulin-resistant subjects show markedly increased fractional DNL >10% (77). DNL is markedly increased by excess dietary CHO, rather than excess dietary fat (78). For example, if total CHO energy intake exceeds total energy expenditure, hepatic DNL is incremented 10-fold (79). Similarly, on a high-CHO diet, DNL synthesis is 27 times increased in the fasting state as compared with a low-CHO diet, and 4 times increased in the fed state (80). Fructose is a primary driver of DNL. Human studies demonstrate a rate of fractional DNL of 2% with glucose and 10% after 6 days of high-fructose feeding (81,82). A recent human study demonstrated that fructose feeding increased fractional DNL to 17% (83).

Dyslipidemia

The attachment of hepatic triglyceride to apoB by MTP completes its conversion to VLDL, which is exported out of the liver to contribute to fructose-induced hypertriglyceridemia (84). Elevated circulating VLDL in animal models of high-fructose feeding may be a result of overproduction (85) driven by insulin resistance; increased triglyceride flux and hepatic inflammation (86); and decreased clearance (87,88).

In rodents, fructose feeding reduces hepatic peroxisome proliferation-activated receptor- α (89); inducing hepatic inflammation (90), and also inducing apoB100 overproduction (85,91), resulting in rapid development of hypertriglyceridemia (92). Similarly, laboratory studies of fructose feeding in humans result in marked increases in serum triglycerides, VLDL, and serum FFA (83,93-95). In children, fructose consumption correlates with the development of “small dense” LDL (96), a lipid particle thought to be particularly atherogenic. These data implicate fructose ingestion as a primary cause of dyslipidemia (77,83,97,98).

Hepatic Lipid Deposition and Steatosis

Some of the fatty acyl-CoA products from DNL escape packaging into VLDL for export, but instead accumulate as lipid droplets in the hepatocyte (3). Similarly, diets that increase carbohydrate response element binding protein activity lead to hepatic lipid deposition by increasing DNL (99) while genetically reducing this pathway reduces hepatic lipid deposition (70).

Animal studies demonstrate increased hepatic lipid deposition in response to high-fructose feeding (92,100). In human studies, eucaloric replacement of glucose with fructose increased intrahepatic lipid levels by 38% within 8 days, as measured by magnetic resonance spectroscopy (81). Although this effect can occur in other states of increased FFA production, eg, type 2 diabetes (101,102), correlative data in obese children between soft drink ingestion and alanine aminotransferase levels (103) suggest a similar pathogenesis. Our group also has also found a correlation between soft drink consumption and alanine aminotransferase levels in obese children (104).

Inflammation, JNK-1, and Hepatic Insulin Resistance

Fructose is able to induce the transcription of the enzyme JNK-1 (105) via activation of mitogen-activated protein kinase kinase 7 (106). In addition, the DNL product DAG can also induce JNK-1 via activation of protein kinase C- ϵ (22). JNK-1 is the bridge between hepatic energy metabolism and inflammation and, once induced, begins the inflammatory cascade (107). As part of its inflammatory action, JNK-1 activation induces serine phosphorylation of insulin receptor substrate-1 (IRS-1) in the liver (108), thereby preventing normal insulin-mediated tyrosine phosphorylation of IRS-1 and promoting hepatic insulin resistance. Alternatively, DAG-induced protein kinase C- ϵ may phosphorylate IRS-1 on a serine moiety directly (109), worsening hepatic insulin resistance.

Animal studies of fructose ingestion demonstrate increases in serine phosphorylation at position 307 of hepatic IRS-1 (110,111) and resultant insulin resistance (112-116). Numerous human studies demonstrate the induction of he-

patic insulin resistance in response to increased fructose feeding (82,83,94) and, in particular, peripheral markers of inflammation (117), although some studies have failed to show induction of insulin resistance (118).

Skeletal Muscle Insulin Resistance

Excessive FFA exported from the liver leads to increased uptake into skeletal muscle. There, DAG reassembled from FFA, reduces glucose transport, resulting in skeletal muscle insulin resistance (119). FFA, liberated from circulating VLDL by insulin stimulation of lipoprotein lipase, also contributes to increased storage of intramyocellular lipid, which perpetuates the insulin resistant state in skeletal muscle (120).

In rodent models, high-fructose feeding increases skeletal muscle lipid deposition and oxidative stress (121) and reduces IRS-1 phosphorylation and PI3-kinase activation in skeletal muscle (112). Similarly, in obese children, intramyocellular lipid correlates with insulin resistance (122); although the primacy of intramyocellular lipid in the genesis of the metabolic syndrome remains controversial (123).

Hyperinsulinemia, Obesity, and Type 2 Diabetes

Hepatic and skeletal muscle insulin resistance, through increases in FFA levels, promotes reciprocal hyperinsulinemia (124). Furthermore, cytokines released from visceral fat into the portal circulation also promotes hepatic insulin resistance, also exacerbating hyperinsulinemia (125). The excess insulin can act peripherally to promote increased adipocyte lipoprotein lipase, which cleaves FFA off circulating VLDL, which is then stored in adipocytes. The resulting obesity causes worsening of the peripheral insulin resistance. Furthermore, fructose increases expression of Foxo1 (126); in the face of hepatic insulin resistance, this Foxo1 cannot all be phosphorylated to maintain its exclusion from the nucleus, and hepatic gluconeogenesis results, raising serum glucose and requiring an even greater β -cell insulin response. Eventually, in response to the hepatic insulin resistance, gluconeogenesis, and the phenomena of glucotoxicity, lipotoxicity, and endoplasmic reticulum stress at the level of the β -cell (127-130), inadequate insulin secretion in relation to the degree of peripheral insulin resistance leads to hyperglycemia and type 2 diabetes (131).

In some animal models, fructose administration leads to insulin resistance and dyslipidemia (92), while in others, full-fledged type 2 diabetes can ensue (132). In humans, sugar-sweetened beverage consumption correlates with prevalence of type 2 diabetes in adults (133-135), while soft drink consumption correlates with obesity and insulin resistance in children (18).

Thus, fructose's action on the liver is unique among carbohydrates and appears independent of insulin. Fructose metabolism gives rise to the phenotype of “selective hepatic insulin resistance” typical of metabolic syndrome by uncoupling effects on gluconeogenesis and DNL. Fructose increases the synthesis of Foxo1 (126), not all of which can be phosphorylated (especially in the face of burgeoning hepatic insulin resistance), allowing gluconeogenesis to drive further insulin need, with resultant hyperglycemia. Fructose also directly increases the syn-

Table. Similarities between soda and beer with respect to hepatic handling

	Soda (12-oz can)	Beer (12-oz can)
Calories	150	150
Percent carbohydrate (%)	10.5 (sucrose)	3.6 (alcohol) 5.3 (other carbohydrates)
Calories from		
Fructose	75 (4.1 kcal/g)	
Alcohol		90 (7 kcal/g)
Other carbohydrate	75 (glucose)	60 (maltose)
First-pass stomach-intestine metabolism (%)	0	10
Calories reaching liver	90	92

thesis of peroxisomal proliferator-activated receptor- γ co-activator-1 β (71), which activates SREBP-1c independently of insulin, promoting DNL to foment dyslipidemia, hepatic steatosis, and further insulin resistance.

Hepatic Metabolic Profile and Substrate Burden: Fructose vs Ethanol

Thus, hepatic metabolism of either fructose or ethanol results in energy substrate conversion to acetyl-CoA, without any insulin regulation and with limited diversion to nontoxic intermediaries such as glycogen. The overwhelming majority of the acetyl-CoA produced will find its way into DNL, generating intrahepatic lipid, inflammation, and insulin resistance. Through the phenomena of enhanced DNL, JNK-1 activation, and hepatic insulin resistance, the hepatic metabolic profile of fructose metabolism parallels that of ethanol.

The hepatic substrate burden between fructose and ethanol are also similar. The Table demonstrates the hepatic burden of a can of beer vs a can of soda. Both contain 150 kcal per 12 oz can. Both contain a glucose load combined with either an ethanol load (beer) or fructose load (soda). The first-pass effect of ethanol in the stomach and intestine removes 10% of the ethanol. In the case of beer (3.6% ethanol and 6.6% maltose, a glucose disaccharide), about 92 calories reach the liver, while for soda, 90 calories reach the liver. Indeed, the metabolic demand on the liver from beer and soda are congruent.

ROS FORMATION

Any carbohydrate can induce ROS formation through actions of its free aldehyde or ketone. The aldehyde form of glucose is reactive with free amino groups on proteins in a nonenzymatic exothermic reaction, leading to nonenzymatic protein glycation (136), termed the *Maillard* or *browning* reaction (eg, hemoglobin A1c). Each glycation generates one superoxide radical, which must be quenched by an antioxidant or cellular damage will occur (137). However, at 37°C and pH 7.4, the majority of glucose molecules are found in the stable six-membered glucopyranose ring form, limiting ROS formation.

Effects of Ethanol

Ethanol induces hepatocellular damage through several different mechanisms (44), including mitochondrial damage, membrane effects, hypoxia, cytokine production, and iron mobilization. In addition, ethanol is thought to exert toxicity through its metabolism by alcohol dehydrogenase 1B to the intermediary acetaldehyde, which, because of its free aldehyde moiety engages rapidly in ROS formation (138). In the absence of antioxidant quenching, these ROS may lead to lipid peroxidation, fibrogenesis, and, ultimately, cirrhosis (Figure 4).

Effects of Fructose

Because the ring form of fructose is a five-membered ring with steric hindrance from the two axial (abutting) hydroxymethyl groups, the linear form is preferred, and the reactive ketone moiety is available for reaction with proteins. In vitro studies demonstrate that fructosylation of proteins with fructose occurs seven times more rapidly than glycation with glucose (139,140). Thus, fructose-generated ROS species are abundant (141,142), which, if not quenched by an antioxidant, can promote hepatocellular damage (Figure 4).

The hepatotoxic effects of fructose via ROS formation have been demonstrated in both cultured hepatocytes (143) and in animal models (144). Although mechanistic data remain lacking in humans, case-controlled studies demonstrate that fructose consumption correlates with development of hepatic steatosis and nonalcoholic steatohepatitis (145,146).

THE HEDONIC PATHWAY OF FOOD REWARD

The limbic structures central to the hedonic pathway that motivates the “reward” of food intake are the ventral tegmental area (VTA) and nucleus accumbens (NA), with inputs from various components of the limbic system, including the striatum, amygdala, hypothalamus, and hippocampus. The NA is also referred to as the “pleasure center” of the brain, as this is the brain area responsive to morphine, nicotine, and ethanol. Food intake is a “read-out” of the reward pathway; for example, administration of morphine to the NA increases food intake in a dose-dependent fashion (147). Dopamine neurotransmission from the VTA to the NA mediate the reward properties of food (148), while obesity results in decreased density of dopamine D₂ receptors as measured by positron emission tomography scanning (149).

Effects of Ethanol

Ethanol is a known substance of abuse through its effects on fostering reward through the hedonic pathway (150). By altering γ -amino-butyric acid and opioid transmission within the VTA and central area of the amygdala, acute ethanol exposure activates dopamine neurotransmission (151). However, following repeated exposure to ethanol, increases in basal dopamine are apparent, but peak effects relative to baseline are decreased, indicating downregulation (152), a postulated mechanism of tolerance. Human genetic studies demonstrate that downregulation of dopamine transport (and resultant inadequate neuro-




Figure 4. Generation of reactive oxygen species (ROS) by fructose or ethanol. Fructose first forms an intermediate Schiff base with the ϵ -amino group of lysine, which then spontaneously hydrogenates to form an irreversible Heyns product (hydroxyamide linkage or fructose adduct), termed the *Maillard reaction*. The heat of formation of this reaction is -19 kcal/mol, and is therefore exothermically favorable. Each protein fructosylation generates one superoxide radical ($O_2^{\bullet-}$), which must be quenched by an antioxidant (such as glutathione with its reduced sulfhydryl groups). Conversely, ethanol is metabolized by alcohol dehydrogenase 1B, generating NADH, to acetaldehyde, which then participates in the same Maillard reaction to form acetaldehyde adducts, with generation of superoxide radicals which must also be quenched by antioxidants. In the absence of adequate antioxidant capacity, ROS production leads to peroxidation, hepatocellular damage, necroinflammation (non-alcoholic steatohepatitis [NASH]), fibrosis, and ultimately cirrhosis. From reference (194): Lim JS, Mietus-Snyder ML, Valente A, Schwarz JM, Lustig RH. Role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. *Nat Rev Gastroenterol Hepatol.* 2010;7:251-264, reprinted with permission.

transmission) results in increased ethanol consumptive behavior (153), and human imaging studies show that dysfunction of dopamine neurotransmission is associated with withdrawal and relapse (154). Such downregulation of dopamine neurotransmission with chronic substrate exposure is a hallmark of the addictive state (155).

Effects of Fructose

Indirect Effects on Reward and Food Intake. Studies in diet-induced obesity document defects in both leptin transport across the blood-brain barrier and in central leptin signaling (156), termed *leptin resistance*. Both leptin and insulin receptors are colocalized in VTA neurons (157), and both hormones have been implicated in modulating rewarding responses to food and other pleasurable stimuli. Leptin decreases VTA-NA activity and extinguishes reward for food (158,159). In the acute situation, insulin

increases expression and activity of the dopamine transporter, which clears and removes dopamine from the synapse (160); thus, acute insulin exposure blunts the reward of food in rats (157). D₂-receptor antagonists and insulin act additively to acutely decrease the rewarding response to a palatable sucrose solution; furthermore, insulin appears to inhibit the ability of VTA-agonists (eg, opioids) to increase intake of sucrose (161). Finally, acute insulin blocks the ability of rats to form a conditioned place-preference association to a palatable food (157).

However, chronic hyperinsulinemia, due to insulin resistance of the sort generated by chronic fructose consumption, may do the opposite; that is, contribute to increased caloric intake by preventing dopamine clearance from the NA, thus fostering pleasure derived from food in situations where energy stores are replete (162). Chronic hyperinsulinemia appears to prevent central leptin signaling (163,164), resulting in leptin resistance and

promotion of further food intake (165,166). Central nervous system insulin resistance sets the stage for unchecked caloric intake in the face of positive energy balance, as evidenced experimentally by the brain-specific insulin receptor knockout mice (167). Thus, by promoting hepatic and muscle insulin resistance, fructose ingestion may alter VTA-NA dopamine neurotransmission, the hedonic response to food, and may drive excessive energy intake. Leptin resistance also results from defective leptin transport across the blood-brain barrier. Recently, one cause of impaired leptin transport has been shown to be hypertriglyceridemia (168), possibly as an adaptation to increase food intake in the face of anorexia and starvation, but maladaptive in the face of fructose-induced dyslipidemia.

Ghrelin, an octanoylated 28-amino acid peptide produced by cells in the stomach, signals the hypothalamus to interpret hunger and increase food intake (169) and fat deposition (170,171). Ghrelin also increases the respiratory quotient in rats, suggesting a reduction of fat oxidation and promotion of fat storage. In humans, ghrelin levels rise with increasing subjective hunger and peak at the time of voluntary food consumption and decrease after meal (172). However, fructose feeding does not decrease ghrelin (93) and, therefore, caloric intake is not suppressed. Indeed, fructose consumption in the form of soft drinks does not reduce the volume of solid food and, therefore, increases the total calories consumed during the meal (24).

Fructose feeding also blunts blood levels of the satiety signal Peptide YY₃₋₃₆ and yields higher levels of hypothalamic endocannabinoid receptor messenger RNA, consistent with increased caloric intake (173). Lastly, fructose reduces hypothalamic malonyl-CoA levels, thought to represent the “fuel gauge” of the neuron, indicating energy inadequacy and promoting increased intake (174,175).

Direct Effects of Fructose on Reward and Food Intake. Fructose also has direct effects on increasing caloric consumption. Increasing the palatability of food by addition of sucrose undermines normal satiety signals and motivates energy intake independent of energy need (176,177). For instance, sucrose infusion directly into the NA reduces D₂ receptors and μ -opioid receptors similar to that of morphine (178). Both sweet and high-fat foods mobilize both opioids and dopamine within the NA and establish hard-wired pathways for craving in these areas that can be identified by functional magnetic resonance imaging (147,179). Furthermore, animal models of intermittent sugar administration, over a 3-week interval, can induce behavioral alterations consistent with dependence; ie, bingeing, withdrawal and anxiety, craving, and cross-sensitization to other drugs of abuse (180). Neuropharmacologic analyses demonstrate reduction in D₂ receptors in the NA, consistent with the fostering of reward and behavioral changes seen in addiction. Although anecdotal reports abound supporting human “sugar addiction,” whether this “vicious cycle” of fructose consumption is merely habituation or full-fledged dependence is not yet clear.

SOCIETAL PARALLELS BETWEEN FRUCTOSE AND ETHANOL

Fructose also has notable societal parallels with ethanol. Both sugar and alcohol are legal and abundantly available substances. Both are treated as “ordinary commodities” in

trade policy (181,182). Problems of overuse and related health harms are more prevalent in lower socioeconomic groups (183,184). Those who overconsume either substance are stigmatized (185,186). Finally, within policy debates, sugar and alcohol involve a parallel set of stakeholders, including industrial producers and distributors, nongovernmental advocacy groups, scientists, clinicians, and two types of government agencies: those charged with promoting economic development and production through trade (eg, US Department of Agriculture) vs those charged with protecting public health (eg, Health and Human Services, Bureau of Alcohol, Tobacco, and Firearms).

SUMMARY AND CONCLUSIONS

Most people consider sugar (ie, fructose-containing compounds) to be just “empty” calories. Although the hepatic metabolic pathways outlined here have been worked out primarily in animal models, the human phenotypes are quite similar. These data indicate that fructose exerts specific biochemical effects beyond its caloric equivalent. In the hypocaloric (eg, starvation) state, fructose is as beneficial as glucose in promoting glycogen repletion (187); but in the hypercaloric state, fructose drives DNL, resulting in dyslipidemia steatosis and insulin resistance akin to that seen with ethanol. The excess acetyl-CoA generated by both substrates overwhelm the mitochondrial TCA cycle, resulting in DNL with resultant dyslipidemia, hepatic lipid deposition, and inflammation. Furthermore, the hepatic insulin resistance results in gluconeogenesis, contributing to hyperglycemia and increasing β -cell insulin strain. In particular, fructose recapitulates the pentad of the metabolic syndrome and has been shown to contribute to cardiovascular disease (30,188). This should not be surprising, as fructose and ethanol are congruent evolutionarily and biochemically. Ethanol is manufactured by fermentation of fructose; the only difference is that for fructose, humans perform the glycolysis, while for ethanol, yeast have already performed the glycolysis. Secondly, through their free reactive carbonyl moieties, both fructose and ethanol produce ROS, which increases risk for hepatocellular damage. Lastly, the neuroendocrine mechanisms outlined here demonstrate that by blocking leptin signaling, promoting sensations of hunger, and activation of the reward pathway, fructose contributes to a positive feedback pathway of continuous ingestion of food independent of energy need, a phenomenon paralleling that of ethanol. Figure 5 lists the overlap in phenotypic phenomena exhibited by fructose and ethanol in a chronic state of overconsumption.

Aside from restriction of intake, there are two “antidotes” to the hepatic effects of fructose. Exercise enacts two benefits. By increasing hepatic TCA cycle maximal velocity (38), less acetyl-CoA will be converted to citrate, providing less substrate for DNL and reducing fructose’s toxic downstream effects. Also, exercise has beneficial effects on both Foxo1 and peroxisomal proliferator-activated receptor- γ coactivator-1 β , thus improving insulin action at the liver (189). Fiber also enjoys two benefits. By reducing glycemic load and rate of carbohydrate absorption, fiber reduces the bolus of energy substrate the liver has to metabolize acutely, thereby reducing the rate of DNL and improving insulin sensitivity (190). Fiber also increases satiety, reducing further consumption (191,

Chronic ethanol exposure	Chronic fructose exposure
<ul style="list-style-type: none"> ● Hematologic disorders ● Electrolyte abnormalities ● Hypertension ● Cardiac dilatation ● Cardiomyopathy 	<ul style="list-style-type: none"> ● Hypertension (uric acid)
<ul style="list-style-type: none"> ● Dyslipidemia ● Pancreatitis ● Obesity (insulin resistance) ● Malnutrition ● Hepatic dysfunction (ASH) ● Fetal alcohol syndrome ● Addiction 	<ul style="list-style-type: none"> ● Myocardial infarction (dyslipidemia, insulin resistance) ● Dyslipidemia (de novo lipogenesis) ● Pancreatitis (hypertriglyceridemia) ● Obesity (insulin resistance) ● Malnutrition (obesity) ● Hepatic dysfunction (NASH)
	<ul style="list-style-type: none"> ● Habituation, if not addiction

Figure 5. Phenotypes of chronic energy substrate exposure. ASH=alcoholic steatohepatitis. NASH=non-alcoholic steatohepatitis.

192). Unfortunately, both of these are currently in short supply in the Western lifestyle.

In order to reduce the cardiovascular sequelae associated with obesity and metabolic syndrome, the American Heart Association has recommended reduction of dietary sugar intake by more than half (30). Enacting such recommendations requires that food and nutrition practitioners reassess their current recommendations. In the process of dispensing “low-fat” dietary directives, an unstated implication is that replacement of fat with carbohydrate is a rational approach. Health care providers must recognize the differences between glucose and fructose and that despite fructose’s classification as a carbohydrate, it is metabolized more like fat. It is this author’s opinion that a low-fat diet in America is tantamount to a high-fat diet, as increased fructose ingestion because of substitution of fructose for fat to improve palatability causes the same metabolic perturbations as does a high-fat diet. Such a formulation also makes it important for the food and nutrition practitioner to assess a patient’s sugar and ethanol consumption separately from their carbohydrate and fat consumption. It is also this author’s opinion that in assessing a patient’s risk for metabolic syndrome, instead of quantifying three macronutrient groups, clinical food and nutrition practitioners should evaluate five, ie, fat, protein, complex carbohydrate, fiber, and sugar/ethanol.

It should be noted that successful efforts to reduce consumption of other stimuli of the hedonic pathway, ie, amphetamine, cocaine, nicotine, cannabis, and ethanol, combine both individual education with some sort of public policy measure, such as taxation, restriction, or interdiction (193). The political, economic, and societal barriers in applying such lessons to reduce fructose consumption are substantial, but not insurmountable. Such policies to curtail fructose consumption, eg, through soda taxation, are currently being debated in New York and California and nationally. Indeed, it seems likely that individual behavioral counseling, combined with sound public health measures, will be necessary to combat this epidemic.

STATEMENT OF POTENTIAL CONFLICT OF INTEREST: No potential conflict of interest was reported by the author.

FUNDING/SUPPORT: The author states categorically that there were no external funding sources relevant to this project or manuscript.

ACKNOWLEDGEMENTS: The author would like to thank Jean-Marc Schwarz, PhD; Kathleen Mulligan, MD; Elissa Epel, PhD; Stanton Glantz, PhD; Neil Benowitz, MD; Laura Schmidt, PhD, MPH; Ronald Krauss, MD; Michele Mietus-Snyder, MD; Kristine Madsen, MD, MPH; Patrika Tsai, MD, MPH; Nathan Bass, MD; Philip Rosenthal, MD; Raphael Merriman, MD; Andrea Garber, PhD, RD; Stephanie Nguyen, MD, MAS; Jung Sub Lim, MD, PhD; and Young Eun Choi, MD, PhD; for their input to this analysis.

References

1. Centers for Disease Control. Trends in intake of energy and macronutrients—United States, 1971-2000. *Morb Mortal Wkly Rep.* 2004; 53:80-82.
2. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease. *Am J Clin Nutr.* 2007;86:285-300.
3. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C. Nonalcoholic fatty liver disease: Predisposing factors and the role of nutrition. *J Nutr Biochem.* 2007;18:184-195.
4. Alkouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: Not all lipids are created equal. *Expert Rev Gastroenterol Hepatol.* 2009;3:445-451.
5. Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: Impact of bariatric surgery. *Semin Liver Dis.* 2008; 28:407-426.
6. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. *Am J Physiol Gastrointest Liver Physiol.* 2008;295:G987-G995.
7. Nagao K, Inoue N, Wang YM, Shirouchi B, Yanagita T. Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. *J Nutr.* 2005;135:9-13.
8. Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. *World J Gastroenterol.* 2009;15: 1809-1815.
9. Channugam P, Guthrie JF, Cecilio S, Morton JF, Basiotis PP, Anand R. Did fat intake in the United States really decline between 1989-1991 and 1994-1996? *J Am Diet Assoc.* 2003;103:867-872.
10. York LW, Puthalappattu S, Wu GY. Nonalcoholic fatty liver disease and low-carbohydrate diets. *Ann Rev Nutr.* 2009;29:365-379.
11. Facchini F, Chen YD, Reaven GM. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. *Diabetes Care.* 1994; 17:115-199.
12. Di Castelnuovo A, Costanzo S, di Giuseppe R, de Gaetano G, Iacoviello L. Alcohol consumption and cardiovascular risk: Mechanisms of action and epidemiologic perspectives. *Future Cardiol.* 2009;5:467-477.
13. Athyros VG, Liberopoulos EN, Mikhailidis DP, Papageorgiou AA, Ganotakis ES, Tziomalos K, Kakafika AI, Karagiannis A, Lambropoulos S, Elisaf M. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. *Angiology.* 2007;58:689-697.
14. Sakurai Y, Umeda T, Shinchi K, Honjo S, Wakabayashi K, Todoroki I, Nishikawa H, Ogawa S, Katsurada M. Relation of total and beverage-specific alcohol intake to body mass index and waist-to-hip ratio: A study of self-defense officials in Japan. *Eur J Epidemiol.* 1997;13:893-898.
15. Baik I, Shin C. Prospective study of alcohol consumption and metabolic syndrome. *Am J Clin Nutr.* 2008;87:1455-1463.
16. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: The Third National Health and Nutrition Examination Survey. *Medscape J Med.* 2008;10:160.
17. Sugar and Sweeteners Team, Market and Trade Economics, Economic Research Service, US Department of Agriculture. US per capita caloric sweeteners estimated deliveries for domestic food and beverage use, by calendar year. <http://www.ers.usda.gov/briefing/Sugar/data/table50.xls>. Accessed March 8, 2010.
18. Ludwig DS, Peterson KE, Gortmaker SL. Relation between con-

- sumption of sugar-sweetened drinks and childhood obesity: A prospective, observational analysis. *Lancet*. 2001;357:505-508.
19. Warner ML, Harley K, Bradman A, Vargas G, Eskenazi B. Soda consumption and overweight status of 2-year-old Mexican-American children in California. *Obesity*. 2006;14:1966-1974.
 20. Faith MS, Dennison BA, Edmunds LS, Stratton HH. Fruit juice intake predicts increased adiposity gain in children from low-income families: Weight status-by-environment interaction. *Pediatrics*. 2006;118:2066-2075.
 21. Le KA, Tappy L. Metabolic effects of fructose. *Curr Opin Nutr Metab Care*. 2006;9:469-475.
 22. Rutledge AC, Adeli K. Fructose and the metabolic syndrome: Pathophysiology and molecular mechanisms. *Nutr Rev*. 2007;65:S13-S23.
 23. Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, Sanchez-Lozada LG. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. *Am J Clin Nutr*. 2007;86:899-906.
 24. Havel PJ. Dietary fructose: Implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. *Nutr Rev*. 2005;63:133-157.
 25. Gross LS, Li S, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: An ecologic assessment. *Am J Clin Nutr*. 2004;79:774-779.
 26. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. *Am J Clin Nutr*. 2002;76:911-922.
 27. Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D'Agostino RB, Gaziano JM, Vasan RS. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. *Circulation*. 2007;116:480-488.
 28. Brown CM, Dulloo AG, Montani JP. Sugary drinks in the pathogenesis of obesity and cardiovascular diseases. *Int J Obes*. 2008;32:528-534.
 29. Bolton-Smith C, Woodward M. Dietary composition and fat to sugar ratios in relation to obesity. *Int J Obes*. 1990;18:820-828.
 30. Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, Sacks F, Steffen L, Wylie-Rosett J, on behalf of the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, and the Council on Epidemiology and Prevention. Dietary sugars intake and cardiovascular health. A scientific statement from the American Heart Association. *Circulation*. 2009;120:1011-1020.
 31. Reaven GM. The metabolic syndrome: Is this diagnosis necessary? *Am J Clin Nutr*. 2006;83:1237-1247.
 32. Brown MS, Goldstein JL. Selective versus total insulin resistance: A pathogenic paradox. *Cell Metab*. 2008;7:95-96.
 33. Naïmi M, Gautier N, Chaussade C, Valverde AM, Acclii D, Van Obberghen E. Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. *Endocrinology*. 2007;148:2424-2434.
 34. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. *Cell Metab*. 2008;8:65-76.
 35. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. *Cell Metab*. 2008;7:125-134.
 36. Bizeau ME, Pagliassotti MJ. Hepatic adaptations to sucrose and fructose. *Metabolism*. 2005;54:1189-1201.
 37. Di Rocco M, Calevo MG, Tarò M, Melis D, Allegri AE, Parenti G. Hepatocellular adenoma and metabolic balance in patients with type 1a glycogen storage disease. *Mol Genet Metab*. 2008;93:398-402.
 38. Glick JL. Effects of exercise on oxidative activities in rat liver mitochondria. *Am J Physiol*. 1966;210:1215-1221.
 39. Tonkonogi M, Sahlin K. Physical exercise and mitochondrial function in human skeletal muscle. *Exerc Sport Sci Rev*. 2002;30:129-137.
 40. Palmieri F. The mitochondrial transporter family (SLC25): Physiological and pathological implications. *Pflugers Arch*. 2004;447:689-709.
 41. Bandsma RH, Prinsen BH, van Der Velden Mde S, Rake JP, Boer T, Smit GP, Reijngoud DJ, Kuipers F. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. *Pediatr Res*. 2008;63:702-707.
 42. Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, Schaefer C, Lieber CS. Gender differences in pharmacokinetics of alcohol. *Alcohol Clin Exp Res*. 2001;25:502-507.
 43. Farfán Labonne BE, Gutiérrez M, Gómez-Quiroz LE, Konigsberg Fainstein M, Bucio L, Souza V, Flores O, Ortíz V, Hernández E, Kershenovich D, Gutiérrez-Ruiz MC. Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage. *Cell Biol Toxicol*. 2009;25:599-609.
 44. Dey A, Cedarbaum AI. Alcohol and oxidative liver injury. *Hepatology*. 2006;43:S63-S74.
 45. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: Role of sterol regulatory element-binding proteins. *Alcohol*. 2004;34:39-43.
 46. Siler SQ, Neese RA, Hellerstein MK. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. *Am J Clin Nutr*. 1999;70:928-936.
 47. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. *Eur J Biochem*. 1997;244:1-14.
 48. Sozio M, Crabb DW. Alcohol and lipid metabolism. *Am J Physiol Endocrinol Metab*. 2008;295:E10-E16.
 49. Garcia-Villafraña J, Guillen A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP activated protein kinase in rat liver. *Biochimie*. 2008;90:460-466.
 50. Guzmán M, Castro J. Alterations in the regulatory properties of hepatic fatty acid oxidation and carnitine palmitoyltransferase I activity after ethanol feeding and withdrawal. *Alcohol Clin Exp Res*. 1990;14:472-477.
 51. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. *J Pharmacol Exp Ther*. 2004;310:417-424.
 52. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? *Hepatology*. 2007;45:1097-1107.
 53. Steinberg D, Pearson TA, Kuller LH. Alcohol and atherosclerosis. *Ann Intern Med*. 1991;114:967-976.
 54. Suter PM, Schutz Y. The effect of exercise, alcohol or both combined on health and physical performance. *Int J Obes*. 2008;32(suppl 6):S48-S52.
 55. Schneider J, Tesdorpf M, Kaffarnik H, Hausmann L, Zöfel P, Zilicken F. Alteration of plasma lipids and intermediates of lipid metabolism in healthy fasting volunteers by ethanol and fructose. *Res Exp Med*. 1976;167:159-170.
 56. Yokoyama H, Hiroshi H, Ohgo H, Hibi T, Saito I. Effects of excessive ethanol consumption on the diagnosis of the metabolic syndrome using its clinical diagnostic criteria. *Intern Med*. 2007;46:1345-1352.
 57. Onishi Y, Honda M, Ogihara T, Sakoda H, Anai M, Fujishiro M, Ono H, Shojima N, Fukushima Y, Inukai K, Katagiri H, Kikuchi M, Oka Y, Asano T. Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation. *Biochem Biophys Res Comm*. 2003;303:788-794.
 58. Lee YJ, Arora AR, Shukla SD. Temporal activation of p42/44 mitogen-activated protein kinase and c-Jun N-terminal kinase by acetaldehyde in rat hepatocytes and its loss after chronic ethanol exposure. *J Pharmacol Exp Ther*. 2002;301:908-914.
 59. Fiaschi E, Baggio B, Favaro S, Antonello A, Camerin E, Todesco S, Borsatti A. Fructose-induced hyperuricemia in essential hypertension. *Metabolism*. 1977;26:1219-1223.
 60. Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. *Kidney Int*. 2008;73:489-496.
 61. Nakagawa T, Tuttle KR, Short R, Johnson RJ. Hypothesis: Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. *Nat Clin Pract Nephrol*. 2006;1:80-86.
 62. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, Shafiq M, Segal M, Glasscock RJ, Shimada M, Roncal C, Nakagawa T. Hypothesis: Could excessive fructose intake and uric acid cause type 2 diabetes? *Endocr Rev*. 2009;30:96-116.
 63. Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. *Am J Physiol Renal Physiol*. 2007;292:F423-F429.
 64. Gao XB, Qi L, Qiao N, Choi HK, Curhan G, Tucker KL, Ascherio A. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. *Hypertension*. 2007;50:306-312.

65. Nguyen S, Choi HK, Lustig RH, Hsu CY. Sugar sweetened beverages, serum uric acid, and blood pressure in adolescents. *J Pediatr*. 2009;154:807-813.
66. Savoca MR, Evans CD, Wilson ME, Harshfield GA, Ludwig DA. The association of caffeinated beverages with blood pressure in adolescents. *Arch Pediatr Adolesc Med*. 2004;158:473-477.
67. Feig DI, Soletsky B, Johnson RJ. Effects of allipurinol on blood pressure of adolescents with newly diagnosed essential hypertension. *JAMA*. 2008;300:924-932.
68. Bonsignore A, Pontremoli S, Mangiarotti G, De Flora A, Mangiarotti M. A direct interconversion: D-fructose 6-phosphate to sedoheptulose 7-phosphate and D-xylulose 5-phosphate catalyzed by the enzymes transketolase and transaldolase. *J Biol Chem*. 1962;237:3597-3602.
69. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. *Proc Natl Acad Sci U S A*. 2003;100:5107-5112.
70. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JRB, Girard J, Postic C. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. *Diabetes*. 2006;55:2159-2170.
71. Nagai Y, Yonemitsu S, Erion DM, Iwasaki T, Stark R, Weismann D, Dong J, Zhang D, Jurczak MJ, Löffler MG, Cresswell J, Yu XX, Murray SF, Bhanot S, Monia BP, Bogan JS, Samuel V, Shulman GI. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. *Cell Metab*. 2009;9:252-264.
72. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. *J Biol Chem*. 1999;274:30028-30032.
73. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. *Clin Sci (Lond)*. 2004;106:635-643.
74. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest*. 2005;115:1343-1351.
75. Leitch CA, Jones PJ. Measurement of human lipogenesis using deuterium incorporation. *J Lipid Res*. 1993;34:157-163.
76. Hellerstein MK, Christiansen M, Kaempfer S, Kletke C, Wu K, Reid JS, Mulligan K, Hellerstein NS, Shackleton CH. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. *J Clin Invest*. 1991;87:1841-1852.
77. Schwarz JM, Linfort P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. *Am J Clin Nutr*. 2003;77:43-50.
78. Schwarz JM, Neese RA, Turner S, Dare D, Hellerstein MK. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. *J Clin Invest*. 1995;96:2735-2743.
79. Aarsland A, Chinkes D, Wolfe RR. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. *J Clin Invest*. 1996;98:2008-2017.
80. Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD, Hirsch J. Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. *J Lipid Res*. 2000;41:595-604.
81. Schwarz JM, Noworolski SM, Lee GA, Wen M, Dyachenko A, Prior J, Weinberg M, Herraiz L, Rao M, Mulligan K. Effects of short-term feeding with high- vs low- fructose isoenergetic diets on hepatic de novo lipogenesis, liver fat content and glucose regulation. *Diabetes*. 2009;1476P abstr.
82. Faeh D, Minehira K, Schwarz JM, Periasami R, Seongsu P, Tappy L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. *Diabetes*. 2005;54:1907-1913.
83. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano C, Beyens C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-, not glucose-sweetened beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *J Clin Invest*. 2009;119:1322-1334.
84. Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease. *Am J Clin Nutr*. 2003;78:873S-880S.
85. Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le Tien H, Fantus IG, Lewis GF, Adeli K. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose fed hamster model of insulin resistance. *J Biol Chem*. 2002;277:793-803.
86. Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: Evidence for a link between hepatic inflammation and lipoprotein production. *Am J Physiol Gastrointest Liver Physiol*. 2009;296:1287-1298.
87. Hirano T, Mamo JC, Poapst ME, Kuksis A, Steiner G. Impaired very low-density lipoprotein-triglyceride catabolism in acute and chronic fructose-fed rats. *Am J Physiol*. 1989;256:E559-E565.
88. Koo HY, Wallig MA, Chung BH, Nara TY, Cho BH, Nakamura MT. Dietary fructose induces a wide range of genes with distinct shift in carbohydrate and lipid metabolism in fed and fasted rat liver. *Biochim Biophys Acta*. 2008;1782:341-348.
89. Roglans N, Vilà L, Farré M, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. *Hepatology*. 2007;45:778-788.
90. Kelley GL, Allan G, Azhar S. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. *Endocrinology*. 2004;145:548-555.
91. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. *J Biol Chem*. 2000;275:8416-8425.
92. Jurgens H, Haass W, Castaneda TR, Schurmans A, Koebnick C, Dombrowski F, Otto B, Nawrocki AR, Scherer PE, Spranger J, Ristow M, Joost HG, Havel PJ, Tschop MH. Consuming fructose-sweetened beverages increases body adiposity in mice. *Obes Res*. 2005;13:1146-1156.
93. Teff KL, Elliott SS, Tschop M, Kieffer TJ, Rader D, Heiman M, Townsend RR, Keim NL, D'Alessio D, Havel PJ. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. *J Clin Endocrinol Metab*. 2004;89:2963-2972.
94. Chong MF, Fielding BA, Frayn KN. Mechanisms for the acute effect of fructose on postprandial lipemia. *Am J Clin Nutr*. 2007;85:1511-1520.
95. Teff KL, Grudziak J, Townsend RR, Dunn TN, Grant RW, Adams SH, Keim NL, Cummings BP, Stanhope KL, Havel PJ. Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: Influence of insulin resistance on plasma triglyceride responses. *J Clin Endocrinol Metab*. 2009;94:1562-1569.
96. Aeberli I, Zimmermann MB, Molinari L, Lehmann R, Allemann D, Spinaz GA, Berneis K. Fructose intake is a predictor of LDL particle size in overweight schoolchildren. *Am J Clin Nutr*. 2007;86:1174-1178.
97. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. *Ann Rev Nutr*. 1996;16:523-557.
98. Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. *Am J Clin Nutr*. 2009;89:1760-1765.
99. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease. *Am J Clin Nutr*. 2007;86:285-300.
100. Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G, Sela BA. Fructose-induced fatty liver disease: Hepatic effects of blood pressure and plasma triglyceride reduction. *Hypertension*. 2005;45:1012-1018.
101. Roden M. Mechanisms of disease: Hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. *Nat Clin Pract Endo Metab*. 2006;2:335-348.
102. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. *J Clin Invest*. 2008;118:829-838.
103. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: Correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. *Int J Obesity*. 2000;24:772-776.
104. Valente A, Mietus-Snyder ML, Lim JS, Lustig RH. Association between sugar sweetened beverage consumption and serum alanine

- aminotransferase in obese children. *Pediatr Acad Soc*. 3854.45 [abstr]. Baltimore, MD: 2009.
105. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem*. 2004;279:32345-32353.
 106. Wei Y, Wang D, Pagliassotti MJ. Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. *J Nutr*. 2005;135:1642-1646.
 107. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. *Nature*. 2002;420:333-336.
 108. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. *Proc Natl Acad Sci U S A*. 2006;103:10741-10746.
 109. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase C-epsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. *J Clin Invest*. 2007;117:739-745.
 110. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Fructose-mediated stress signaling in the liver: Implications for hepatic insulin resistance. *J Nutr Biochem*. 2007;18:1-9.
 111. Kelley GL, Allan G, Azhar S. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. *Endocrinology* 2004;145:548-555.
 112. Bezerra RMN, Ueno M, Silva MS, Tavares DQ, Carvalho CRO, Saad MJA. A high fructose diet affects the early steps of insulin action in muscle and liver of rats. *J Nutr*. 2000;130:1531-1535.
 113. Melancon S, Bachelard H, Badeau M, Bourgoin F, Pitre M, Lariviere R, Nadeau A. Effects of high-sucrose feeding on insulin resistance and hemodynamic responses to insulin in spontaneously hypertensive rats. *Am J Physiol Heart Circ Physiol*. 2006;290:2571-2581.
 114. Gonsolin D, Couturier K, Garait B, Rondel S, Novel-Chate V, Peltier S, Faure P, Gachon P, Boirie Y, Keriel C, Favier R, Pepe S, Demaison L, Leverve X. High dietary sucrose triggers hyperinsulinemia, increases myocardial β -oxidation, reduces glycolytic flux, and delays post-ischemic contractile recovery. *Mol Cell Biochem*. 2007;295:217-228.
 115. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol Cell*. 2000;6:87-97.
 116. D'Angelo G, Elmarakby AA, Pollock DM, Stepp DW. Fructose feeding increases insulin resistance but not blood pressure in Sprague-Dawley rats. *Hypertension*. 2005;46:806-811.
 117. Sorensen LB, Raben A, Stender S, Astrup A. Effect of sucrose on inflammatory markers in overweight humans. *Am J Clin Nutr*. 2005;82:421-427.
 118. Lê KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, Boesch C, Ravussin E, Tappy L. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. *Am J Clin Nutr*. 2006;84:1374-1379.
 119. Montell E, Turini M, Marotta M, Roberts M, Noé V, Ciudad CJ, Macé K, Gómez-Foix AM. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. *Am J Physiol Endocrinol Metab*. 2001;280:E229-E237.
 120. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A ^1H -NMR spectroscopy study. *Diabetologia*. 1999;42:113-116.
 121. Rajasekar P, Anuradha CV. Effect of L-carnitine on skeletal muscle lipids and oxidative stress in rats fed high-fructose diet. *Exp Diabetes Res*. 2007;2007:72741.
 122. Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, Ma YZ, Savoye M, Rothman DL, Shulman GI, Caprio S. Assessment of skeletal muscle triglyceride content by ^1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: Relationships to insulin sensitivity, total body fat, and central adiposity. *Diabetes*. 2002;51:1022-1027.
 123. Hesselink MKC, Mensink M, Schrauwen P. Intramyocellular lipids and insulin sensitivity: Does size really matter? *Obesity Res*. 2004;12:741-742.
 124. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. *Diabetes*. 2003;52:2453-2460.
 125. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, Bergman RN. Molecular evidence supporting the portal theory: A causative link between visceral adiposity and hepatic insulin resistance. *Am J Physiol Endocrinol Metab*. 2004;288:E454-E461.
 126. Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, Tse T, Jiang Y, Dong HH. PPAR γ mediates the hypolipidemic action of fibrates by antagonizing FoxO1. *Am J Physiol Endocrinol Metab*. 2007;292:E421-E434.
 127. Poyntout V, Robertson RP. Glucolipotoxicity: Fuel excess and beta-cell dysfunction. *Endocr Rev*. 2008;29:351-366.
 128. Cnop M, Igoillo-Esteve M, Cunha DA, Ladrière L, Eizirik DL. An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells. *Biochem Soc Trans*. 2008;36:909-915.
 129. Liu M, Hodish I, Rhodes CJ, Arvan P. Proinsulin maturation, misfolding, and proteotoxicity. *Proc Natl Acad Sci U S A*. 2007;104:15841-15846.
 130. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. *Int J Obes*. 2008;32:S52-S54.
 131. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: The hyperbolic correction. *Diabetes*. 2002;51:S212-S220.
 132. Lewis GF, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A, Adeli K, Brunzell JD. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. *Diabetes*. 2004;53:2893-2900.
 133. Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. *JAMA*. 2004;292:927-934.
 134. Montonen J, Järvinen R, Knekt P, Heliövaara M, Reunanen A. Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. *J Nutr*. 2007;137:1447-1454.
 135. Palmer JR, Boggs DA, Krishnan S, Hu FB, Singer M, Rosenberg L. Sugar-sweetened beverages and incidence of type 2 diabetes mellitus in African American women. *Arch Intern Med*. 2008;168:1487-1492.
 136. Dills WL. Protein fructosylation: Fructose and the Maillard reaction. *Am J Clin Nutr*. 1993;58:779S-787S.
 137. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. *Rev Endocrinol Metab Dis*. 2008;9:301-314.
 138. Niemelä O, Parkkila S, Ylä-Herttuala S, Villanueva J, Ruebner B, Halsted CH. Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. *Hepatology*. 1995;22:1208-1214.
 139. Ahmed N, Furth AJ. Failure of common glycation assays to detect glycation by fructose. *Clin Chem*. 1992;38:1301-1303.
 140. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: Sweet coupling or bad modification. *Diabetes Metab Res*. 2004;20:369-382.
 141. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: Possible evolutionary significance. *Science*. 1981;213:222-224.
 142. Bose T, Chakraborti AS. Fructose-induced structural and functional modifications of hemoglobin: Implication for oxidative stress in diabetes mellitus. *Biochim Biophys Acta*. 2008;1780:800-808.
 143. Lee O, Bruce WR, Dong Q, Bruce J, Mehta R, O'Brien PJ. Fructose and carbonyl metabolites and endogenous toxins. *Chem Biol Interact*. 2009;178:332-339.
 144. Pickens MK, Yan JS, Ng RK, Ogata H, Grenert JP, Beysen C, Turner SM, Maher JJ. Dietary sucrose is essential to the development of liver injury in the MCD model of steatohepatitis. *J Lipid Res*. 2009;50:2072-2082.
 145. Assy N, Nasser G, Kamayse I, Nseir W, Beniasvili Z, Djibre A, Grosovski M. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. *Can J Gastroenterol*. 2008;22:811-816.
 146. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. *J Hepatol*. 2009;51:918-924.
 147. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M. Opioid modulation of taste hedonics within the ventral striatum. *Physiol Behav*. 2002;76:365-377.
 148. Carr KD, Tsimberg Y, Berman Y, Yamamoto N. Evidence of increased dopamine receptor signaling in food-restricted rats. *Neuroscience*. 2003;119:1157-1167.
 149. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS. Brain dopamine and obesity. *Lancet*. 2001;357:354-357.
 150. Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyttiä P,

- Merlo-Pich E, Weiss F. Neurocircuitry targets in ethanol reward and dependence. *Alcohol Clin Exp Res*. 1998;22:3-9.
151. Melis M, Diana M, Enrico P, Marinelli M, Brodie MS. Ethanol and acetaldehyde action on central dopamine systems: Mechanisms, modulation, and relationship to stress. *Alcohol*. 2009;43:531-539.
152. Philpot RM, Wecker L, Kirstein CL. Repeated ethanol exposure during adolescence alters the developmental trajectory of dopaminergic output from the nucleus accumbens septi. *Int J Dev Neurosci*. 2009;27:805-815.
153. Lind PA, Eriksson CJ, Wilhelmsen KC. Association between harmful alcohol consumption behavior and dopamine transporter (DAT1) gene polymorphisms in a male Finnish population. *Psychiatr Genet*. 2009;19:117-125.
154. Heinz A, Beck A, Grüsser SM, Grace AA, Wrase J. Identifying the neural circuitry of alcohol craving and relapse vulnerability. *Addict Biol*. 2009;14:108-118.
155. Tupala E, Tiihonen J. Dopamine and alcoholism: Neurobiological basis of ethanol abuse. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004;28:1221-1247.
156. El-Hashimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. *J Clin Invest*. 2000;105:1827-1832.
157. Figlewicz DP. Adiposity signals and food reward: Expanding the CNS roles of insulin and leptin. *Am J Physiol Regul Integr Comp Physiol*. 2003;284:R882-R892.
158. Farooqi IS, Bullmore E, Keogh J, Guillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. *Science*. 2007;317:1355.
159. Shalev U, Yap J, Shaham Y. Leptin attenuates food deprivation-induced relapse to heroin seeking. *J Neurosci*. 2001;21:RC129:121-125.
160. Carvelli L, Morón JA, Kahlig KM, Ferrer JV, Sen N, Lechleiter JD, Leeb-Lundberg LM, Merrill G, Lafer EM, Ballou LM, Shippenberg TS, Javitch JA, Lin RZ, Galli A. PI3-kinase regulation of dopamine uptake. *J Neurochem*. 2002;81:859-869.
161. Sipols AJ, Bayer J, Bennett R, Figlewicz DP. Intraventricular insulin decreases kappa opioid-mediated sucrose intake in rats. *Peptides*. 2002;23:2181-2187.
162. Anderzhanova E, Covasa M, Hajnal A. Altered basal and stimulated accumbens dopamine release in obese OLETF rats as a function of age and diabetic status. *Am J Physiol Regul Integr Comp Physiol*. 2007;293:R603-R611.
163. Kellerer M, Lammers R, Fritsche A, Strack V, Machicao F, Borboni P, Ullrich A, Häring HU. Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase-2: A potential mechanism for hyperinsulinaemia-associated leptin resistance. *Diabetologia*. 2001;44:1125-1132.
164. Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, Cowley MA, Cantley LC, Lowell BB, Elmquist JK. Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. *J Clin Invest*. 2008;118:1796-1805.
165. Han JC, Rutledge MS, Kozlosky M, Salaita CG, Gustafson JK, Keil MF, Fleisch AF, Roberts MD, Ning C, Yanovski JA. Insulin resistance, hyperinsulinemia, and energy intake in overweight children. *J Pediatr*. 2008;152:612-617.
166. Lustig RH. Childhood obesity: Behavioral aberration or biochemical drive? Reinterpreting the First Law of Thermodynamics. *Nat Clin Pract Endocrinol Metab*. 2006;2:447-458.
167. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. *Science*. 2000;289:2122-2125.
168. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, Morley JE. Triglycerides induce leptin resistance at the blood-brain barrier. *Diabetes*. 2004;53:1253-1260.
169. Druce MR, Neary NM, Small CJ, Milton J, Monteiro M, Patterson M, Ghatei MA, Bloom SR. Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. *Int J Obes*. 2006;30:293-296.
170. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. *Endocrinology*. 2000;141:4797-4800.
171. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. *Nature*. 2000;407:908-913.
172. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BF, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes*. 2001;50:1714-1719.
173. Lindqvist A, Baelemans A, Erlanson-Albertsson C. Effects of sucrose, glucose and fructose on peripheral and central appetite signals. *Regul Pept*. 2008;150:26-32.
174. Cha SH, Wolfgang M, Tokutake Y, Chohnan S, Lane MD. Differential effects of central fructose and glucose on hypothalamic malonyl-CoA and food intake. *Proc Natl Acad Sci U S A*. 2008;105:16871-16875.
175. Lane MD, Cha SH. Effect of glucose and fructose on food intake via malonyl-CoA signaling in the brain. *Biochem Biophys Res Comm*. 2009;382:1-5.
176. Erlanson-Albertsson C. How palatable food disrupts appetite regulation. *Basic Clin Pharmacol Toxicol*. 2005;97:61-73.
177. Pelchat ML. Of human bondage: Food craving, obsession, compulsion, and addiction. *Physiol Behav*. 2002;76:347-352.
178. Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Opiate-like effects of sugar on gene expression in reward areas of the rat brain. *Mol Brain Res*. 2004;124:134-142.
179. Pelchat ML, Johnson A, Chan R, Valdez J, Ragland JD. Images of desire: Food-craving activation during fMRI. *Neuroimage*. 2004;23:1486-1493.
180. Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. *Neurosci Biobehav Rev*. 2008;32:20-39.
181. Casswell S, Thamarangsi T. Reducing harm from alcohol: Call to action. *Lancet*. 2009;373:2247-2257.
182. Cannon G. Why the Bush administration and the global sugar industry are determined to demolish the 2004 WHO global strategy on diet, physical activity and health. *Public Health Nutr*. 2004;7:369-380.
183. Bleich SN, Wang YC, Wang Y, Gortmaker SL. Increasing consumption of sugar-sweetened beverages among US adults: 1988-1994 to 1999-2004. *Am J Clin Nutr*. 2009;89:372-381.
184. Keyes KM, Hasin DS. Socio-economic status and problem alcohol use: The positive relationship between income and the DSM-IV alcohol abuse diagnosis. *Addiction*. 2008;103:1120-1130.
185. Puhl RM, Heuer CA. Obesity stigma: Important considerations for public health. *Am J Public Health*. 2010;100:1019-1028.
186. Mulia N, Ye Y, Greenfield TK, Zemore SE. Disparities in alcohol-related problems among white, black, and Hispanic Americans. *Alcohol Clin Exp Res*. 2009;33:654-662.
187. Burelle Y, Lamoureux MC, Péronnet F, Massicotte D, Lavoie C. Comparison of exogenous glucose, fructose and galactose oxidation during exercise using 13C-labelling. *Br J Nutr*. 2006;96:56-61.
188. Fung TT, Malik V, Rexrode KM, J.E. M, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. *Am J Clin Nutr*. 2009;89:1037-1042.
189. Ropelle E, Pauli JR, Cintra D, Frederico M, Pinho RA, Velloso LA, De Souza CT. Acute exercise modulates the Foxo1/PGC-1alpha pathway in the liver of diet-induced obesity rats. *J Physiol*. 2009;587:2069-2076.
190. Liese AD, Schulz M, Fang F, Wolever TM, D'Agostino RB, Sparks KC, Mayer-Davis EJ. Dietary glycemic index and glycemic load, carbohydrate and fiber intake, and measures of insulin sensitivity, secretion, and adiposity in the Insulin Resistance Atherosclerosis Study. *Diabetes Care*. 2005;28:2832-2838.
191. Martlett JA, McBurney MI, Slavin JL. Position of the American Dietetic Association: Health implications of dietary fiber. *J Am Diet Assoc*. 2002;102:993-1000.
192. Pereira MA, Ludwig DS. Dietary fiber and body weight regulation. Observations and mechanisms. *Pediatr Clin North Am*. 2001;48:969-980.
193. Royal College of Physicians. Alcohol and Public Health: The Prevention of Harm Related to the Use of Alcohol. Hampshire, UK: MacMillan; 1991.
194. Lim JS, Mietus-Snyder ML, Valente A, Schwarz JM, Lustig RH. Role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. *Nat Rev Gastroenterol Hepatol*. 2010;7:251-264.

 American Dietetic Association

Evidence Analysis Library®

For additional information on this topic, visit

ADA's Evidence Analysis Library at
www.adaevidencelibrary.com